Biocept to Collaborate with Quest Diagnostics to Provide Advanced NGS-Based Liquid Biopsy Testing for Patients with Lung Cancer

Author's Avatar
Jun 22, 2021

Biocept%2C+Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced a collaboration with Quest Diagnostics (NYSE: DGX) to provide laboratory testing services to Quest patients for its Target Selector™ NGS-based liquid biopsy targeted lung cancer panel. Quest Diagnostics is the leading provider of diagnostic information services, including in advanced diagnostics.